Family Medicine | Page 127 of 374 | Links Medicus Content Curation & Alerts in Medicine

Study suggests that the safety benefits of sleeve gastrectomy persist up to 5 years after surgery; this information may help patients and surgeons make informed treatment decisions https://t.co/JuRQGh3byz

— JAMA Surgery (@JAMASurgery) October 6, 2021

The Dutch Multidisciplinary Occupational Health Guideline to Enhance Work Participation Among Low Back Pain and Lumbosacral Radicular Syndrome Patients.

7 Oct, 2021 | 10:18h | UTC

The Dutch Multidisciplinary Occupational Health Guideline to Enhance Work Participation Among Low Back Pain and Lumbosacral Radicular Syndrome Patients – Journal of Occupational Rehabilitation

Opinion | Why Are Americans Still—Still!—Wearing Cloth Masks?

6 Oct, 2021 | 10:04h | UTC

Why Are Americans Still—Still!—Wearing Cloth Masks? – The Atlantic

Evidence shows that, yes, masks prevent COVID-19 – and surgical masks are the way to go.

Face masks for COVID pass their largest test yet – “A rigorous study finds that surgical masks are highly protective, but cloth masks fall short”.

[Preprint] Largest study of masks yet details their importance in fighting Covid-19.

Commentary on Twitter

Any mask is better than no mask, especially indoors. But for those who are at higher risk of severe disease or around lots of unvaccinated people, consider upgrading to an N95 (or equivalent) mask, which are more protective. https://t.co/vhNPadTP8O

— Dr. Tom Frieden (@DrTomFrieden) October 5, 2021

EMA recommendations on extra doses and boosters of BioNTech/Pfizer and Moderna mRNA vaccines.

6 Oct, 2021 | 10:15h | UTC

Comirnaty and Spikevax: EMA recommendations on extra doses and boosters – European Medicines Agency

Commentary on Twitter

EMA recommended additional doses and boosters for #Comirnaty and #Spikevax. https://t.co/qefPg2kMMO

In this context, see below what the difference between an additional dose and a #boosterdose is. pic.twitter.com/HeyOACbWXm

— EU Medicines Agency (@EMA_News) October 5, 2021

What we know — and don’t know — about Merck’s new Covid-19 pill.

6 Oct, 2021 | 10:07h | UTC

What we know — and don’t know — about Merck’s new Covid-19 pill – STAT

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Cohort study: Adding a new antihypertensive to existing regimens is associated with greater blood pressure reductions than maximizing dose.

6 Oct, 2021 | 09:57h | UTC

Adding a New Medication Versus Maximizing Dose to Intensify Hypertension Treatment in Older Adults: A Prospective Observational Study – Annals of Internal Medicine

News release: When blood pressure needs more control, what’s better: An additional drug or more of the same? – Michigan Medicine

Commentary: Adding an antihypertensive to existing regimens associated with greater BP reduction than maximizing dose, with some caveats in adherence – ACP Internist

Commentary on Twitter (thread – click for more)

Excited to see our paper in Annals today looking at blood pressure control regiments by adding multiple low dose meds vs. maxing dose then starting new meds. 🧵 https://t.co/3d4L2nZO4v

— Jeremy Sussman (@JeremySussman) October 5, 2021

Supplement: Triumphs of Vaccination.

6 Oct, 2021 | 08:55h | UTC

Homepage: Triumphs of Vaccination – The Journal of Infectious Diseases

Triumphs of Immunization

Pertussis (Whooping Cough)

Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease

The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease

Hepatitis B Vaccines

Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe

Rubella Eradication: Not Yet Accomplished, but Entirely Feasible

Human Papillomavirus Vaccines

Smallpox

Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster

Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication

Influenza Vaccines: Successes and Continuing Challenges

Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination

Herpes Zoster Vaccines

Overview of the United States’ Immunization Program

The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade

Review: Eosinophilic Esophagitis.

6 Oct, 2021 | 09:51h | UTC

Eosinophilic Esophagitis: A Review – JAMA (free for a limited period)

Randomized trial: Budesonide orodispersible tablets maintain remission in patients with eosinophilic esophagitis

Clinical Guidelines for the Management of Eosinophilic Esophagitis

Eosinophilic Esophagitis: Review and Update

Is salt good for you after all? The evidence says no.

6 Oct, 2021 | 08:52h | UTC

Is salt good for you after all? The evidence says no – The Conversation

#ESCCongress – Cluster RCT: Among patients at increased risk for stroke, salt substitution (75% sodium chloride and 25% potassium chloride by mass) reduced the rates of stroke, major cardiovascular events, and death from any cause.

Systematic Review: Altered dietary salt intake for people with chronic kidney disease.

New WHO benchmarks help countries reduce salt intake and save lives.

RCT: Reduced-sodium added-potassium salt substitute reduces blood pressure in hypertensive patients

Potassium Enriched Salt Substitution Could Prevent a Large Number of Cardiovascular Deaths

Meta-Analysis: Effect of Reduction in Dietary Sodium on Blood Pressure Levels

Cluster Randomized Trial: Effect of Salt Substitution on Community-wide Blood Pressure and Hypertension Incidence

Cohort study: Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older is rare, and most cases are not severe.

5 Oct, 2021 | 10:07h | UTC

Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older – JAMA Internal Medicine

Editorial: COVID-19 Messenger RNA Vaccination and Myocarditis—A Rare and Mostly Mild Adverse Effect

Commentary on Twitter

New report on very rare acute myocarditis after mRNA vaccination in age 18+
5.8 cases/million after 2nd dose, 0.8/million 1st dose, all cases fully resolved with conservative managementhttps://t.co/Mfh5ImiSpW @KPSCALnews @KPSCalResearch @JAMAInternalMed

— Eric Topol (@EricTopol) October 4, 2021

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

5 Oct, 2021 | 10:09h | UTC

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study – The Lancet

Commentary: Expert reaction to study on Pfizer-BioNTech vaccine effectiveness up to 6 months – Science Media Centre

Commentary on Twitter

Study of 3.4 million people @aboutKP @TheLancet

Vaccine efficacy against infections:
– First month post: 88%
– 5 months post: 47%

But vaccine efficacy against hospitalization (Figure):
– First month post: 87%
– 5 months post: 88 %https://t.co/1Gse0FKpoI pic.twitter.com/p9wyiaWGeg

— Vincent Rajkumar (@VincentRK) October 4, 2021

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

5 Oct, 2021 | 09:57h | UTC

A Pill For COVID? | A Doctor Explains Molnupiravir – ZDoggMD

Merck’s Covid-19 pill is great news but may not be a game-changer.

5 Oct, 2021 | 09:59h | UTC

Merck’s Covid-19 pill is great news but may not be a game-changer – CNN

Cohort study: Statin therapy initiation linked to increased risk of diabetes progression.

5 Oct, 2021 | 08:56h | UTC

Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study – JAMA Internal Medicine

Commentaries:

Statin Therapy Initiation and Diabetes Progression – American College of Cardiology

Statin Initiation Linked to Greater Progression of Diabetes – HealthDay

Diabetes progression with initiation of statins – MedicalRessearch.com

Meta-Analysis: Medications that Reduce or Increase the Risk of New Onset Diabetes

Observational Study Points to an Increased Risk of Diabetes Among Patients Using Statins

Another Observational Study Showing Association of Statin Use with Risk of New‐Onset Diabetes Mellitus

Cohort Study: Statin Use Associated with a 38% Higher Risk of Incident Type 2 Diabetes

Commentary on Twitter

Large retrospective matched-cohort study found that #statin use was associated with a higher risk of #diabetes treatment escalation and an increased risk of #hyperglycemic complications https://t.co/lFLz7rVfpd

— JAMA Internal Medicine (@JAMAInternalMed) October 4, 2021

Podcast: Urinary Stone Disease.

5 Oct, 2021 | 08:50h | UTC

#298 Urinary Stone Disease Will Rock Your World – The Curbsiders

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

3 Oct, 2021 | 23:02h | UTC

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

Commentaries:

Expert reaction to interim analysis of oral antiviral molnupiravir – Science Media Centre

Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment – STAT

Covid antiviral pill can halve risk of hospitalization – BBC

Why Merck’s Covid-19 pill molnupiravir could be so important – Vox

‘Unquestionably a game changer!’ Antiviral pill cuts COVID-19 hospitalization risk – Researchers excited about Merck drug, but caution data are preliminary and price is high – Science

Commentaries on Twitter

.@DrEricDing convinced many that stopping the #molnupiravir trial early for benefit was a good idea

But it was NOT

Large body of evidence suggests that stopping early for benefit biases the results: overestimates the benefits of the treatment #EBM https://t.co/b3tHEtliO0 https://t.co/LwuCgqcY0C pic.twitter.com/vyPWc0nd37

— Kari Tikkinen (@KariTikkinen) October 2, 2021

(thread – click for more)

💡BREAKING—New oral anti-viral drug *molnupiravir* cuts risk of #COVID19 hospitalization and death **in HALF** in a randomized trial. Results so astounding that the trial is being stopped early, and Merck plans to apply for emergency authorization ASAP. 🧵 https://t.co/g8JGNzvuRg pic.twitter.com/K1SwC3QFXS

— Eric Feigl-Ding (@DrEricDing) October 1, 2021

New analysis shows benefits of offering two doses of COVID-19 vaccine to children aged 12-17 clearly outweigh risks.

3 Oct, 2021 | 22:52h | UTC

News release: New analysis shows benefits of offering two doses of COVID-19 vaccine to children aged 12-17 clearly outweigh risks – The Royal Society of Medicine

Original report: Vaccinating adolescents against SARS-CoV-2 in England: a risk-benefit analysis

Editorial | Clinical ethics: consent for vaccination in children.

3 Oct, 2021 | 22:53h | UTC

Clinical ethics: consent for vaccination in children – Archives of Disease in Childhood

Systematic Review: Is exercise an effective therapy to treat long-lasting low back pain?

3 Oct, 2021 | 22:32h | UTC

Summary: Is exercise an effective therapy to treat long-lasting low back pain? – Cochrane Library

Original Study: Exercise therapy for chronic low back pain – Cochrane Library

Commentary on Twitter

https://twitter.com/CochraneUK/status/1444221879502483456

ADA Consensus Report: The Management of Type 1 Diabetes in Adults.

3 Oct, 2021 | 22:38h | UTC

The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) – Diabetologia

News release: New comprehensive Consensus Report to manage type 1 diabetes launched by major diabetes organisations EASD and ADA – American Associatio of Diabetes

Commentary on Twitter

What a fantastic symposium on the management of #T1D at #EASD2021! Read the full ADA–EASD consensus report here https://t.co/8cEm8N0Enr pic.twitter.com/uMj2R64CkK

— Diabetologia (@DiabetologiaJnl) October 1, 2021